Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time
- 12 July 2016
- journal article
- review article
- Published by Wiley in Reviews in Medical Virology
- Vol. 26 (6) , 408-434
Abstract
Summary: The introduction of highly potent direct‐acting antivirals (DAAs) has revolutionized hepatitis C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the era of DAA treatment, because of the high associated costs, high numbers of undiagnosed patients, high re‐infection rates in some risk groups and suboptimal drug efficacies associated with host and viral factors as well as advanced stages of liver disease. A correct determination of the HCV genotype allows administration of the most appropriate antiviral regimen. Additionally, HCV genetic sequencing improves our understanding of resistance‐associated variants, either naturally occurring before treatment, acquired by transmission at HCV infection, or emerging after virological failure. Because treatment response rates, and the prevalence and development of drug resistance variants differ for each DAA regimen and HCV genotype, this review summarizes treatment opportunities per HCV genotype, and focuses on viral genetic sequencing to guide clinical decision making. Although approval of the first pan‐genotypic DAA‐only regimen is expected soon, HCV genetic sequencing will remain important because when DAA therapies fail, genotyping and resistance testing to select a new active DAA combination will be essential. Copyright © 2016 John Wiley & Sons, Ltd.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (G.A029.11N)
This publication has 141 references indexed in Scilit:
- Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studiesVirology, 2013
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Directly acting antivirals against hepatitis C virusJournal of Antimicrobial Chemotherapy, 2011
- A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis CClinical Gastroenterology and Hepatology, 2011
- Evaluation of three different hepatitis C virus typing methods for detection of mixed-genotype infectionsJournal of Digestive Diseases, 2011
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C VirusScience Translational Medicine, 2010
- High incidence of hepatitis C virus reinfection within a cohort of injecting drug usersJournal of Viral Hepatitis, 2006
- Epidemiology of viral hepatitis and HIV co-infectionJournal of Hepatology, 2006
- Hepatitis C virus mixed genotype infection in patients on haemodialysisJournal of Viral Hepatitis, 2000
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989